Novartis Builds On Its Legacy With Scemblix Approval For CML

US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.

Legacy Concept
Novartis is building on its legacy in CML with a new drug • Source: Alamy

More from New Products

More from Scrip